Insider Transactions in Q2 2025 at Relmada Therapeutics, Inc. (RLMD)
Insider Transaction List (Q2 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 20
2025
|
Sergio Traversa Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
147,686
+16.75%
|
$0
$0.56 P/Share
|
|
May 20
2025
|
Maged Shenouda Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
60,000
+17.22%
|
$0
$0.52 P/Share
|
|
May 19
2025
|
Sergio Traversa Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
30,000
+4.87%
|
$0
$0.5 P/Share
|
|
May 19
2025
|
Maged Shenouda Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
90,000
+28.27%
|
$0
$0.49 P/Share
|
|
May 16
2025
|
Sergio Traversa Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
172,314
+23.65%
|
$0
$0.45 P/Share
|
|
May 16
2025
|
Chuck Ence CA and CO |
BUY
Open market or private purchase
|
Direct |
228,961
+46.08%
|
$0
$0.45 P/Share
|
|
May 16
2025
|
Maged Shenouda Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
50,000
+26.55%
|
$0
$0.44 P/Share
|
|
May 16
2025
|
Paul Edward Kelly Chief Operating Officer |
BUY
Open market or private purchase
|
Direct |
200,000
+32.66%
|
$0
$0.43 P/Share
|